Pharmacyclics, Inc. (NASSDAQ:PCYC) And Servier Strike Deal To End Collaboration On Pan-HDAC Inhibitor

Boston, MA 09/26/2014 (wallstreetpr) – Biopharmaceutical company, Pharmacyclics, Inc. (NASDAQ:PCYC) disclosed that it has struck an agreement with French pharmaceutical company, Servier, paving the way for ending the collaboration relating to pan-HDAC inhibitor compounds. Collaboration Ends The company said that the agreement was mutual and amicable, its statement indicated. As a result, abexinostat compound would […]

The FDA Approves Pharmacyclics, Inc. (NASDAQ:PCYC)’s Filing For Supplemental New Drug Application For Drug IMBRUVICA

Boston, MA 06/10/2014 (wallstreetpr) – Pharmacyclics, Inc. (NASDAQ:PCYC) announced that the U.S. Food and Drug Administration has agreed to file its supplemental New Drug Application in support of the review of its drug IMBRUVICA for the treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma for complete approval. The supplemental NDA is useful in the […]

Most Mentioned Stocks: Altria Group Inc (NYSE:MO), Health Care REIT, Inc. (NYSE:HCN), Pharmacyclics, Inc. (NASDAQ:PCYC)

Boston, MA 06/03/2014 (wallstreetpr) – Altria Group Inc (NYSE:MO) will pay a quarterly dividend of $0.48 per share on July 10, to shareholders who will have acquired its share by June 16. The newly declared quarterly dividend represents 4.73 percent on annualized basis.  The company has kept a good fight in the cigarette industry, and […]